Need Help?
Copied to clipboard!

Longitudinal Analysis of Multiple Myeloma: Bone Marrow Recovery and Immune Microenvironment Dynamics in the Context of Tumor Heterogeneity

Multiple myeloma (MM) is a hematologic malignancy characterized by expansion of malignant plasma cells in the bone marrow. In newly diagnosed MM (NDMM), standard triplet regimens such as bortezomib, lenalidomide, and dexamethasone (VRd), along with the more recent addition of an anti-CD38 monoclonal antibody, have improved outcomes by targeting complementary mechanisms. Treatment typically includes several cycles of induction therapy, high-dose melphalan (HDM) with autologous stem cell transplantation (ASCT), and maintenance therapy. Responses vary widely, with some patients requiring prolonged or intensified therapy and others achieving deeper remissions more quickly. Despite these advances, most patients ultimately relapse, and MM remains incurable.

This study characterizes tumor state and the immune microenvironment across therapy in NDMM and in a second cohort of relapsed/refractory MM (RRMM). For NDMM, longitudinal blood and bone marrow aspirate samples were collected at diagnosis, during induction, after ASCT, and at post-transplant intervals of 60 days, 90 days, and 1 and 2 years. Additional NDMM PBMC RNA-seq data include a longitudinal influenza series in years 1 and 2 post-transplant, sampled at days 0, 7, and 90. For RRMM, bone marrow samples were collected prior to CD38-targeted therapy, after the 8th dose (before biweekly dosing began), and at progression. Blood was collected after 2, 4, 6, and 8 weeks of therapy and again at 4, 6, 9, 12, 18, and 24 months. When scheduled, blood was also collected around influenza vaccination at days 0, 7, and 90.

Multi-omic profiling of these samples captures heterogeneity in tumor biology and therapeutic response while enabling within-patient longitudinal analyses. Using Olink proteomics in plasma and bone marrow interstitial fluid (BMIF), and single-cell profiling (3′ CITE-seq, scRNA-seq, and flow cytometry) of peripheral blood mononuclear cells (PBMCs) and bone marrow mononuclear cells (BMMCs), we longitudinally characterized tumor cells, the immune microenvironment, and treatment-associated remodeling. These data identify distinct immune states and pathways associated with therapeutic response and tumor persistence, and they highlight potential targets and strategies to improve outcomes.

For additional healthy sample data, please go to phs003400, phs003841, and phs003944 to access the sequence data for these samples.